Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, named CID (Cilio-scleral Inter-positioning Device), today announces that the interim results of a 12-month follow-up study on its groundbreaking CID concept show strong potential to mark a new era in glaucoma surgery.
